Bausch + Lomb and Clearside Biomedical Announce Publication of Pivotal Phase 3 Data on Xipere in Ophthalmology
January 29, 2020
January 29, 2020
BRIDGEWATER, New Jersey, Jan. 29 -- Bausch + Lomb issued the following news release:
Bausch + Lomb, a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), and Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that Ophthalmology, the peer-revie . . .
Bausch + Lomb, a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), and Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that Ophthalmology, the peer-revie . . .